mercredi 5 décembre 2018

Onco Actu du 5 décembre 2018


3.4 Chimioprévention

Can Topical Drugs Help Prevent Breast Cancer? [NCI]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

FDA takes new action to advance the development of reliable and beneficial genetic tests that can improve patient care [FDA]

4.10 Dép., diag. & prono. - Poumon

Lung cancer screening part 1: the benefits and harms according to clinical trials [Cancer Research UK]

4.12 Biopsies liquides

One test to diagnose them all: researchers exploit cancers’ unique DNA signature [The Conversation]

Scientists develop 10-minute universal cancer test [The Guardian]

GRAIL Announces Plans to Initiate SUMMIT Study to Support Development of Blood Test for Early Cancer Detection [GRAIL]

5. Traitements

Last Month in Oncology with Dr. Bishal Gyawali: November 2018 [ecancer News]

5.12.5 Immunothérapies - Pharma

Roche's Tecentriq wins speedy U.S. FDA review for small cell lung cancer [Reuters]

FDA Grants Priority Review to Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer [Genentech]

5.2 Pharma

Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma [Exelixis]

5.7 SABCS

SWOG Shares Trio of Studies in San Antonio [SWOG]

5.8 ASH

ASH Highlights for Tuesday, December 4, 2018 [OBR]

5.8.1 ASH - Communiqués

Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma [ASH]

5.8.2 ASH - Pharma

Bispecifics vs CAR-T: Analysts select the big winners — and losers — at #ASH18’s biggest ever datapalooza [EndPoints]

5.8.3 ASH - Divers

ASH: Can Johnson & Johnson sell regulators on Xarelto as clot prevention for cancer patients? [FiercePharma]

New Phase 3 CASSINI Data Presented on the Use of XARELTO® (rivaroxaban) for Venous Thromboembolism (VTE) Prevention in High-Risk Cancer Patients [Johnson&Johson]

5.8.4 ASH - CAR T

Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma [Johnson&Johnson]

Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia [Allogene]

BCMA Day: At ASH ‘18, Cell Therapies For Myeloma Take Center Stage [Xconomy]

5.8.5 ASH - Myélome multiple

ASH: Johnson & Johnson's fast-growing Darzalex lines up for 2nd front-line myeloma OK [FiercePharma]

New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma [Johnson&Johnson]

Johnson & Johnson's multiple myeloma drug reduces risk of death in late-stage study [Reuters]

5.8.6 ASH - Leucémies

ASH: Johnson & Johnson, AbbVie's Imbruvica steals the CLL spotlight with phase 3 study wins [FiercePharma]

New Phase 3 Study Findings Show IMBRUVICA® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia [Johnson&Johnson]

IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients; Late-Breaking Phase 3 Data at ASH 2018 [AbbVie]

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia [NIH]

JNJ-AbbVie cancer drug Imbruvica succeeds in late-stage trial [Reuters]

6.1 Observation

5 million healthy Britons will be tracked in bid to detect disease sooner [The Telegraph]

6.6 Publications

Researchers sign petition backing plans to end paywalls [Nature]